InsiderPulse
Dashboard

ALNY

Alnylam Pharmaceuticals, Inc.

Health CareRussell 2000

Alnylam Pharmaceuticals, Inc. insider trading

Alnylam Pharmaceuticals, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Cambridge, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent ALNY insider transactions

4 insiders traded ALNY on the open market between Mar 05, 2026 and Jun 01, 2026 — 24 sales worth $3.2M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$3.2M

24 of 24 on a 10b5-1 plan

Net
−$3.2M
Insiders
4

Open-market purchases (code P) and sales (code S) from Alnylam Pharmaceuticals, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every ALNY Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

ALNY insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 11 insiders traded ALNY on the open market: 2 purchases worth $10.4K and 645 sales worth $162.1M, 318 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 423 sales ($89.3M), by 10 insiders.

QuarterBoughtSold
Q2 2026—−$2.4M19 sales · all on a plan
Q1 2026—−$24M228 sales · 86 on a plan
Q4 2025—−$27.3M96 sales · 48 on a plan
Q3 2025—−$35.5M80 sales · 48 on a plan
Q2 2025—−$18.7M18 sales · 17 on a plan
Q1 2025—−$29.1M152 sales · 68 on a plan
Q4 2024+$1.2K1 buy−$3.7M36 sales · 16 on a plan
Q3 2024+$9.2K1 buy−$21.4M16 sales · all on a plan
Largest purchase
+$9.2K of ALNY by Reitan Colleen F (Director) on Aug 29, 2024.
Largest sale
−$15M of ALNY by Garg Pushkal (CMO & EVP Dev & Med Affairs) on Jan 27, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Fitzgerald Kevin Joseph10b5-1

    CSO & EVP, Head of Research

    −$75.3K

    Mar 05, 2026

    233 sh · $323.25

  • Fitzgerald Kevin Joseph10b5-1

    CSO & EVP, Head of Research

    −$49.9K

    Mar 05, 2026

    153 sh · $326.24

  • Fitzgerald Kevin Joseph10b5-1

    CSO & EVP, Head of Research

    −$48K

    Mar 05, 2026

    148 sh · $324.60

  • Greenstreet Yvonne

    Chief Executive Officer · Director

    −$315.1K

    Mar 04, 2026

    973 sh · $323.84

  • Poulton Jeffrey V.

    EVP, Chief Financial Officer

    −$264.9K

    Mar 04, 2026

    818 sh · $323.84

  • Garg Pushkal10b5-1

    EVP Chief R&D

    −$248.4K

    Mar 04, 2026

    767 sh · $323.84

  • Tanguler Tolga

    EVP, Chief Commercial Officer

    −$248.4K

    Mar 04, 2026

    767 sh · $323.84

  • Greenstreet Yvonne

    Chief Executive Officer · Director

    −$143.4K

    Mar 04, 2026

    444 sh · $323.01

  • Poulton Jeffrey V.

    EVP, Chief Financial Officer

    −$120.8K

    Mar 04, 2026

    374 sh · $323.01

  • Greenstreet Yvonne

    Chief Executive Officer · Director

    −$118.4K

    Mar 04, 2026

    368 sh · $321.82

  • Garg Pushkal10b5-1

    EVP Chief R&D

    −$113.1K

    Mar 04, 2026

    350 sh · $323.01

  • Tanguler Tolga

    EVP, Chief Commercial Officer

    −$113.1K

    Mar 04, 2026

    350 sh · $323.01

  • Greenstreet Yvonne

    Chief Executive Officer · Director

    −$112.1K

    Mar 04, 2026

    345 sh · $324.88

  • Poulton Jeffrey V.

    EVP, Chief Financial Officer

    −$99.4K

    Mar 04, 2026

    309 sh · $321.82

  • Poulton Jeffrey V.

    EVP, Chief Financial Officer

    −$94.5K

    Mar 04, 2026

    291 sh · $324.88

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Alnylam Pharmaceuticals, Inc. company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Cambridge, MA
Listed on
Nasdaq
SEC Central Index Key
0001178670

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought ALNY

What the stock actually did in the 90 days following each open-market purchase

Don't check ALNY — let it ping you

Get told the moment an insider moves on ALNY

Pro watches Alnylam Pharmaceuticals, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add ALNY to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track ALNY on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read ALNY insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

BMRNINCYJAZZHALOEXASNTRACRSPNTLABEAMRXRXTWSTPACB
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are ALNY insiders buying or selling?
Between Mar 05, 2026 and Jun 01, 2026, 4 Alnylam Pharmaceuticals, Inc. insiders made no open-market purchases and 24 sales worth $3.2M, a net sale of $3.2M. 24 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much ALNY stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 11 Alnylam Pharmaceuticals, Inc. insiders made 2 open-market purchases worth $10.4K and 645 sales worth $162.1M. 318 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 423 sales ($89.3M). The largest purchase was Reitan Colleen F buying $9.2K on Aug 29, 2024. The largest sale was Garg Pushkal selling $15M on Jan 27, 2025.
What was the largest recent ALNY insider trade?
Pyott David E I (Director) sold $366.4K of ALNY stock on Jun 01, 2026 at about $299.87 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy ALNY shares?
No open-market purchase by a Alnylam Pharmaceuticals, Inc. insider appears in the filings from Mar 05, 2026 to Jun 01, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Reitan Colleen F buying $1.2K on Oct 17, 2024.
Where does ALNY insider trading data come from?
From the Form 4 filings Alnylam Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.